What is the drug of choice for a patient diagnosed with syndrome of inappropriate antidiuretic hormone?

Affiliations

  • PMID: 3121240

Review

Management of the syndrome of inappropriate secretion of antidiuretic hormone

B J Kinzie. Clin Pharm. 1987 Aug.

Abstract

The etiology, pathophysiology, clinical features, diagnosis, and medical treatment of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) are reviewed. SIADH is a common cause of hyponatremia in hospitalized patients. Increased concentrations of antidiuretic hormone (ADH) result in retention of free water, increased excretion of sodium, and hyponatremia. Symptoms generally occur only when hyponatremia is severe (less than or equal to 125 meq/L) and may include anorexia, vomiting, and confusion, followed by seizures, coma, and death. SIADH may result from a variety of diseases, as well as from the use of drugs such as chlorpropamide, carbamazepine, diuretics, and some antineoplastic agents. Diagnosis of SIADH is confirmed by demonstration of a high urine osmolality with a low plasma osmolality, in the absence of diuretic use. Immediate treatment of the symptomatic patient with SIADH includes intravenous furosemide and 3% sodium chloride injection to produce a negative free-water balance. If the underlying cause of SIADH cannot be corrected, the treatment of choice for chronic SIADH is fluid restriction. If this is not tolerated by the patient, demeclocycline can be used to induce a negative free-water balance. Urea, lithium, phenytoin, and loop diuretics have been reported to be effective, but there are few data to support their use. Future research into the treatment of SIADH must be directed at developing effective antagonists of ADH. Treatment of SIADH consists of elimination of underlying causes and restriction of fluid intake; if these measures are unsuccessful or poorly tolerated, long-term drug therapy may be indicated.

Similar articles

  • [Hyponatremia secondary to inappropriate antidiuretic hormone secretion].

    Zamboli P, De Nicola L, Minutolo R, Iodice C, Avino D, Mascia S, D'Angiò P, Calabria M, Conte G. Zamboli P, et al. G Ital Nefrol. 2008 Sep-Oct;25(5):554-61. G Ital Nefrol. 2008. PMID: 18985840 Italian.

  • Clinical laboratory evaluation of the syndrome of inappropriate secretion of antidiuretic hormone.

    Decaux G, Musch W. Decaux G, et al. Clin J Am Soc Nephrol. 2008 Jul;3(4):1175-84. doi: 10.2215/CJN.04431007. Epub 2008 Apr 23. Clin J Am Soc Nephrol. 2008. PMID: 18434618 Review.

  • Management of hyponatremia.

    Goh KP. Goh KP. Am Fam Physician. 2004 May 15;69(10):2387-94. Am Fam Physician. 2004. PMID: 15168958 Review.

  • The syndrome of inappropriate secretion of antidiuretic hormone (SIADH).

    Decaux G. Decaux G. Semin Nephrol. 2009 May;29(3):239-56. doi: 10.1016/j.semnephrol.2009.03.005. Semin Nephrol. 2009. PMID: 19523572

Cited by

  • A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis.

    Refardt J, Imber C, Sailer CO, Jeanloz N, Potasso L, Kutz A, Widmer A, Urwyler SA, Ebrahimi F, Vogt DR, Winzeler B, Christ-Crain M. Refardt J, et al. J Am Soc Nephrol. 2020 Mar;31(3):615-624. doi: 10.1681/ASN.2019090944. Epub 2020 Feb 4. J Am Soc Nephrol. 2020. PMID: 32019783 Free PMC article. Clinical Trial.

  • Copeptin and its role in the diagnosis of diabetes insipidus and the syndrome of inappropriate antidiuresis.

    Refardt J, Winzeler B, Christ-Crain M. Refardt J, et al. Clin Endocrinol (Oxf). 2019 Jul;91(1):22-32. doi: 10.1111/cen.13991. Epub 2019 May 8. Clin Endocrinol (Oxf). 2019. PMID: 31004513 Free PMC article. Review.

  • Empagliflozin Increases Short-Term Urinary Volume Output in Artificially Induced Syndrome of Inappropriate Antidiuresis.

    Refardt J, Winzeler B, Meienberg F, Vogt DR, Christ-Crain M. Refardt J, et al. Int J Endocrinol. 2017;2017:7815690. doi: 10.1155/2017/7815690. Epub 2017 Dec 20. Int J Endocrinol. 2017. PMID: 29422914 Free PMC article.

  • Fluid, electrolyte and acid-base disorders associated with antibiotic therapy.

    Zietse R, Zoutendijk R, Hoorn EJ. Zietse R, et al. Nat Rev Nephrol. 2009 Apr;5(4):193-202. doi: 10.1038/nrneph.2009.17. Nat Rev Nephrol. 2009. PMID: 19322184 Review.

  • Diagnosis and management of hyponatremia in cancer patients.

    Raftopoulos H. Raftopoulos H. Support Care Cancer. 2007 Dec;15(12):1341-7. doi: 10.1007/s00520-007-0309-9. Epub 2007 Aug 14. Support Care Cancer. 2007. PMID: 17701059 Review.

Publication types

MeSH terms

Substances

What is the drug of choice for SIADH?

Medication Summary Urea is used for the treatment of SIADH refractory to or in patients noncompliant with other therapies or when other therapies are not available. Urea is known to promote diuresis. It decreases brain edema, restores medullary tonicity, and induces Na+ retention.

What intervention should be done for a patient with syndrome of inappropriate antidiuretic hormone?

The most commonly prescribed treatment for SIADH is fluid and water restriction. If the condition is chronic, fluid restriction may need to be permanent. Treatment may also include: Certain medications that inhibit the action of ADH (also called vasopressin)

Which diuretic is used in SIADH?

Loop diuretics induce a copious water diuresis in SIADH [Decaux et al. 1981; Hantman et al. 1973]. Furosemide may be given orally or intravenously in a dosage as high as 10–40 mg/h, with or without replacement of any sodium lost by infusions of 3% saline.

Why is vasopressin used in SIADH?

Vasopressin (also called antidiuretic hormone) helps regulate the amount of water in the body by controlling how much water is excreted by the kidneys. Vasopressin decreases water excretion by the kidneys. As a result, more water is retained in the body, which dilutes the level of sodium in the body.